Search Results

Press Releases

Invenra Inc. and Xcellon Biologics Announce Collaboration to Advance Bispecific and Trispecific Antibody-Drug Conjugate (ADC) Development

October 22, 2025

·

4 min read

Press Releases

Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board

July 15, 2025

·

4 min read

Press Releases

Invenra Launches T-Body™ Trispecific Platform to Advance Next-Generation Therapeutic Antibodies

May 13, 2025

·

3 min read

Business

Invenra Inc. Announces a Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs

Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in innovative drug development solutions.

April 2, 2024

·

1 min read

BioMidwest

Invenra Inc. Announces a Strategic Research Agreement with Astellas Pharma in Therapeutic Bispecific Antibody Discovery

Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic research agreement with Astellas Pharma, a global pharmaceutical company with a vision to turn innovative science into value for patients.

April 9, 2024

·

1 min read

Press Releases

Invenra Highlights Exelixis’ Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

May 14, 2025

·

1 min read

Press Releases

Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics

January 31, 2025

·

2 min read

Press Releases

Invenra and Orion Announce Discovery Service and Commercial License Agreement to Develop Innovative Bispecific Antibody Cancer Therapeutics

January 30, 2025

·

2 min read

Press Releases

Invenra Welcomes Three Industry Leaders to Its Board of Directors

September 17, 2024

·

3 min read

Drug Development

Invenra to Present Preclinical Data on INV322, A Next Generation Tumor Treg Depleter

Invenra announced that Chief Scientific Officer Daniel Pereira, Ph.D., will present preclinical data supporting the ongoing development of INV322, an antibody-based cancer therapeutic.

September 20, 2022

·

3 min read